CYP Induction - Creative Proteomics Dmpk

Introduction Isoform Coverage Technical Advantages Workflow & QC Demo Results Case Study Technical Selection Sample Requirements FAQ

Introduction to Cytochrome P450 Induction

In the drug discovery landscape of 2026, Cytochrome P450 (CYP) induction is a primary determinant of lead compound success. Induction is an adaptive, transcriptionally mediated response where a xenobiotic increases the synthesis and activity of metabolic enzymes. Unlike inhibition, which is an immediate blockage, induction is a slower process requiring de novo protein synthesis. When a compound acts as a ligand for specific nuclear receptors, it triggers a signaling cascade that upregulates enzyme expression at the genomic level.

The primary consequence of CYP induction is an accelerated clearance rate for co-administered therapeutic agents, which can lead to sub-therapeutic plasma concentrations and loss of efficacy. Furthermore, some compounds exhibit auto-induction, where the drug induces its own metabolism over time. At Creative Proteomics DMPK, our professional induction platform is engineered to resolve these complex kinetics using high-resolution analytical tools. We provide objective experimental evidence in an ISO 17025-certified environment, allowing researchers to identify potential metabolic "accelerators" early. This assessment is often performed in parallel with our CYP Inhibition Assay to fully map the drug-drug interaction (DDI) risk profile.

Comprehensive Isoform Coverage and Validated Panel

A thorough metabolic evaluation requires the assessment of multiple CYP isoforms regulated by distinct nuclear receptor pathways. Our platform provides validated induction assays for the primary isoforms involved in human drug metabolism.

CYP Isoform	Primary Induction Pathway	Positive Control Inducer	Validated Probe Substrate	Measured Metabolite
CYP1A2	AhR (Aryl Hydrocarbon Receptor)	Omeprazole	Phenacetin	Acetaminophen
CYP2B6	CAR (Constitutive Androstane Receptor)	Phenobarbital	Bupropion	Hydroxybupropion
CYP3A4/5	PXR (Pregnane X Receptor)	Rifampicin	Midazolam	1'-hydroxymidazolam
CYP2C9	PXR / CAR Cross-talk	Rifampicin	Diclofenac	4'-hydroxydiclofenac
CYP2C19	PXR / CAR Cross-talk	Rifampicin	S-Mephenytoin	4'-hydroxymephenytoin

Each experiment is conducted with strict control over substrate concentrations, typically maintained at the Michaelis constant ($K_m$). High-sensitivity measurement is facilitated by our Single Drug Quantification Services, providing the pg/mL detection limits necessary for analyzing low-volume cellular supernatants.

Technical Advantages in Induction Profiling

Our platform is engineered to overcome common pitfalls associated with in vitro induction screening, particularly for challenging compounds.

Superior LC-MS/MS Sensitivity: We utilize high-resolution mass spectrometry (Triple Quadrupole or Orbitrap) to quantify probe metabolites. By employing stable isotope-labeled internal standards, we ensure that even subtle induction effects (e.g., < 2-fold) are detected with confidence.
Non-specific Binding (NSB) Mitigation: Many lead compounds are lipophilic and adsorb to plastic surfaces. This underestimates the actual exposure of hepatocytes. We utilize specialized low-adsorption labware and optimized incubation buffers to minimize these effects, ensuring accurate Emax and EC50 determination.
Automated High-Throughput qRT-PCR: Our genomic workflow utilizes automated RNA extraction to measure mRNA levels across multiple isoforms. This ensures transcriptional upregulation is accurately captured before functional activity manifests.
Integrated Cytotoxicity Screening: To avoid false-positives caused by cellular stress, we conduct parallel viability assays (ATP or LDH). Induction data is only considered valid if cell viability remains ≥ 80%.

Standardized Workflow & QC

We implement a rigorous 6-step workflow to ensure every project is conducted with full traceability.

Hepatocyte Quality Assessment: Thawing and seeding Primary Human Hepatocytes (PHH) or HepaRG™ cells into collagen-coated plates. Baseline metabolic activity is verified.
Compound Dosing: Test compounds are applied in a minimum of 7 to 10 concentrations (typically 0.01 µM to 100 µM) to capture a full sigmoidal curve.
72-Hour Induction Exposure: Cells are exposed for 72 hours, with media refreshed every 24 hours to maintain constant compound concentration and cell health.
Automated Endpoint Retrieval: Cells are harvested for RNA extraction, and supernatants are collected for functional activity assessment via probe substrate incubation.
Dual-Endpoint Measurement: mRNA levels are quantified via qRT-PCR for fold-induction analysis; enzymatic activity is measured using LC-MS/MS for metabolite formation.
Kinetic Modeling: Non-linear regression analysis calculates the maximum induction effect ($E_{max}$) and the potency ($EC_{50}$).

Quality Control: CV < 15% across replicates and a Signal-to-Noise (S/N) ratio > 10 at the LLOQ.

Standardized 6-step workflow for CYP induction assay

Demo Results: Deliverables and Visualization

We deliver professional data packages designed for immediate lead ranking.

mRNA Fold-Induction Charts: Bar graphs illustrating fold-change in mRNA expression relative to vehicle and positive controls.
Sigmoidal Dose-Response Curves: High-resolution fitting plots for EC50 and Emax determination.
Relative Induction Correlation: Scatter plots correlating transcriptional upregulation (mRNA) against functional metabolic output (LC-MS/MS Activity).
High-Resolution Chromatograms: Authentic LC-MS/MS traces showing metabolite quantification with clear peak separation.

Representative mRNA fold-induction bar charts for CYP isoforms

Sigmoidal dose-response curve for Emax and EC50 determination

Cell viability curves ensuring reliable induction data

Case Study: Validating CYP3A4 Induction in 3D Liver MPS

Source Reference

Adapted from Sakolish et al., Archives of Toxicology, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12967466/

Background

This multi-center study evaluated the potential of varied liver microphysiological system (MPS) configurations to model complex biochemical effects, using CYP induction as a marker of physiological relevance.

Methods

PHH and HepaRG™ cells were cultured in 2D monolayers and 3D MPS platforms (e.g., PhysioMimix™) and exposed to Bosentan (25 µM) for 72 hours.

Results

As demonstrated in Figure 4 of the original research, the 3D MPS platforms provided more robust and sustained induction of CYP3A4 mRNA levels compared to 2D cultures, exhibiting higher physiological correlation.

Conclusion

These findings validate our integration of advanced 3D liver models. To characterize metabolites formed through induced pathways, our MetID Services can be integrated for structural elucidation.

Comparative study: CYP3A4 induction in 2D vs 3D Microphysiological Systems

Technical Selection Strategy

Selecting the appropriate assay depth is critical for balancing research budgets with scientific certainty.

Study Tier	Type	Application	Key Deliverable
Tier 1	Screening	High-throughput lead ranking.	% Induction at 10 µM.
Tier 2	mRNA Profiling	Standard lead optimization and SAR.	7-point mRNA induction curve.
Tier 3	Dual Track Study	Definitive DDI risk assessment.	mRNA + LC-MS/MS Activity data.
Tier 4	3D MPS Study	Chronic exposure research.	3D MPS induction kinetics.

Sample Requirements & Logistics

Form: Crystalline powder (≥ 5 mg) or 10 mM DMSO stock solution.
Purity: ≥ 95% confirmed by analytical report.
Logistics: Samples must be shipped on dry ice to ensure chemical stability. We provide a comprehensive guide to maintain an ISO 17025-compliant chain of custody from your facility to our lab. This ensures results can be integrated with other studies, such as our Transporter Inhibition services.

Frequently Asked Questions (FAQ)

Why is mRNA measured instead of just enzyme activity?

mRNA quantification via qRT-PCR is a more sensitive and direct indicator of nuclear receptor activation. Measuring activity confirms that upregulation has a functional impact on metabolic capacity.

How do you handle poorly soluble or highly lipophilic compounds?

We utilize specialized low-protein binding materials and perform pre-assay solubility testing. If a compound precipitates, we adjust co-solvent ratios or utilize microfluidic platforms to optimize exposure kinetics.

What is the typical turnaround time for an induction study?

We typically provide preliminary results within 4 weeks of sample receipt, allowing for hepatocyte recovery, the 72-hour exposure cycle, and analytical quantification.

High-Resolution CYP Induction Assay & EC50 Determination Services